Merck Gets $200m In Gilead Patent Case, But Who Wins?
This article was originally published in Scrip
A jury in the US District Court for the Northern District of California, which decided earlier in the week that Gilead Sciences Inc. infringed two of Merck & Co. Inc.'s hepatitis C drug patents, determined on March 24 that Gilead should pay its rival $200m – a sum much lower than what Merck sought when the companies' patent dispute began in 2013.
You may also be interested in...
Merck to appeal decision after district court says Gilead's discovery of sofosbuvir was 'neither routine nor simple.'
Patent brawl between Merck and Gilead involving Sovaldi and Harvoni was one of the marquee litigation events of 2016; a compilation of disputes between brand-name companies over the past six years shows how consequential they can be.
Will $2.5Bn Jury Verdict Against Gilead Stand? Future Royalties, Willful Infringement Penalty Uncertain
Gilead is appealing a jury finding that it must pay Merck 10% royalty on sales of Sovaldi and Harvoni through August 2016; judge could find the firm owes treble the amount for willful infringement.